Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8056 to 8070 of 8941 results

  1. Hepatitis C (genotype 1, chronic) - faldaprevir [ID670]

    Discontinued Reference number: GID-TAG456

    Technology appraisal guidance
    Discontinued

  2. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

    Technology appraisal guidance
    Discontinued

  3. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued Reference number: GID-TAG482

    Technology appraisal guidance
    Discontinued

  4. Vorapaxar for reducing atherothrombotic events after a myocardial infarction or in peripheral vascular disease [ID616]

    Discontinued Reference number: GID-TAG493

    Technology appraisal guidance
    Discontinued

  5. Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]

    Discontinued Reference number: GID-TAG494

    Technology appraisal guidance
    Discontinued

  6. Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657]

    Discontinued Reference number: GID-TAG496

    Technology appraisal guidance
    Discontinued

  7. Pacritinib for treating myelofibrosis [ID880]

    Discontinued Reference number: GID-TA10133

    Technology appraisal guidance
    Discontinued

  8. Elotuzumab for untreated multiple myeloma [ID966]

    Discontinued Reference number: GID-TA10134

    Technology appraisal guidance
    Discontinued

  9. Nintedanib for previously treated metastatic colorectal cancer [ID1030]

    Discontinued Reference number: GID-TA10138

    Technology appraisal guidance
    Discontinued

  10. Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]

    Discontinued Reference number: GID-TA10140

    Technology appraisal guidance
    Discontinued

  11. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]

    Discontinued Reference number: GID-TA10144

    Technology appraisal guidance
    Discontinued

  12. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued Reference number: GID-TA10148

    Technology appraisal guidance
    Discontinued

  13. Bevacizumab for treating recurrent glioblastoma [ID978]

    Discontinued Reference number: GID-TA10149

    Technology appraisal guidance
    Discontinued

  14. Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

    Discontinued Reference number: GID-TA10151

    Technology appraisal guidance
    Discontinued

  15. Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

    Discontinued Reference number: GID-TA10154

    Technology appraisal guidance
    Discontinued